Avenue Therapeutics, Inc. (ATXI)
OTCMKTS · Delayed Price · Currency is USD
0.5800
-0.0100 (-1.69%)
Aug 22, 2025, 4:00 PM EDT
Avenue Therapeutics Company Description
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases.
The company product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; and intravenous tramadol for the treatment of post-operative acute pain.
It also develops BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida.
Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Avenue Therapeutics, Inc.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Alexandra MacLean |
Contact Details
Address: 1111 Kane Concourse Bay Harbor Islands, Delaware 33154 United States | |
| Phone | 781 652 4500 |
| Website | avenuetx.com |
Stock Details
| Ticker Symbol | ATXI |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US05360L3042 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alexandra MacLean M.D. | Chief Executive Officer and Director |
| David Jin | Interim Chief Financial Officer, Chief Operating Officer and Corporate Secretary |
| Dr. Lindsay Allan Rosenwald M.D. | Executive Director |
| Dr. Scott A. Reines M.D., Ph.D. | Interim Chief Medical Officer |